Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Protocol 2: Intermediate approach (experienced researchers) Goal: Multi-target immune modulation with anti-inflammatory support Components: Thymosin alpha-1: 1.6 mg subcutaneously, three times weekly KPV: 200-500 mcg subcutaneously, once daily BPC-157: 250 mcg subcutaneously, twice daily Selank: 250-500 mcg intranasally, once daily Schedule: Monday, Wednesday, Friday: Thymosin alpha-1 Daily AM: KPV + BPC-157 Daily PM: BPC-157 Daily: Selank nasal spray (morning or midday) Duration: 12 weeks on, 4 weeks off Monitoring: Baseline labs, repeat every 4 weeks
J.NicolaA
10.1016/j.eclinm.2020.100458 60 El-KenawiA
Ensure F2F documentation is complete and signed
US$ 27.43
US$ 23.88
US$ 24.88
US$ 22.20
US$ 29.07
US$ 22.23
:max_bytes(150000):strip_icc()/Health-GLP1-pill-vs-shot-137cf589ddca421bb0aef5c5d7aec64a.png)
